{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T20:51:37Z","timestamp":1785099097108,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T00:00:00Z","timestamp":1541808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10620-018-5365-0","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T06:44:35Z","timestamp":1541832275000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan"],"prefix":"10.1007","volume":"64","author":[{"given":"Kouichi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Fujie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takeichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Murao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiwamu","family":"Hasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoharu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuie","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,10]]},"reference":[{"key":"5365_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"Y Fujiwara","year":"2009","unstructured":"Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518\u2013534.","journal-title":"J Gastroenterol."},{"key":"5365_CR2","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.3748\/wjg.v19.i39.6523","volume":"19","author":"A Altomare","year":"2013","unstructured":"Altomare A, Guarino MP, Cocca S, Emerenziani S, Cicala M. Gastroesophageal reflux disease: update on inflammation and symptom perception. World J Gastroenterol. 2013;19:6523\u20136528.","journal-title":"World J Gastroenterol."},{"key":"5365_CR3","first-page":"93","volume":"72","author":"D Armstrong","year":"1999","unstructured":"Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med. 1999;72:93\u2013100.","journal-title":"Yale J Biol Med."},{"key":"5365_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00535-008-2257-7","volume":"43","author":"M Hongo","year":"2008","unstructured":"Hongo M, Kinoshita Y, Miwa H, Ashida K. The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. J Gastroenterol. 2008;43:920\u2013927.","journal-title":"J Gastroenterol."},{"key":"5365_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2036.2005.02558.x","volume":"22","author":"F Pace","year":"2005","unstructured":"Pace F, Negrini C, Wiklund I, Rossi C, Savarino V, The Italian One Investigators Study Group. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349\u2013356.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u2013767.","journal-title":"J Gastroenterol."},{"key":"5365_CR7","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"P Miner Jr","year":"2003","unstructured":"Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616\u20132620.","journal-title":"Am J Gastroenterol."},{"key":"5365_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R Fass","year":"2005","unstructured":"Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2014where next? Aliment Pharmacol Ther. 2005;22:79\u201394.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF03262211","volume":"16","author":"T Furuta","year":"2012","unstructured":"Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16:223\u2013234.","journal-title":"Mol Diagn Ther."},{"key":"5365_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","volume":"108","author":"K Andersson","year":"2005","unstructured":"Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294\u2013307.","journal-title":"Pharmacol Ther."},{"key":"5365_CR11","unstructured":"Drug approval review for vonoprazan fumarate (in Japanese). The Pharmaceuticals and Medical Devices Agency of Japan. 2014. Available at: \n                    http:\/\/www.pmda.go.jp\/drugs\/2014\/P201400173\/index.html\n                    \n                  . Accessed May 28, 2015."},{"key":"5365_CR12","unstructured":"The Interview Form for Vonoprazan Fumarate (Takecab Tablets 10\u00a0mg and 20\u00a0mg) ver. 3, (in Japanese). Takeda Pharmaceutical Company Limited. 2015. Available at: \n                    http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/400256_2329030F1020_1_005._1F\n                    \n                  . Accessed May 28, 2015."},{"key":"5365_CR13","unstructured":"Prescribing information of Takecab tablets 10\u00a0mg and 20\u00a0mg ver.2 (in Japanese). 2015. Available at: \n                    http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSet\n                    \n                  . Accessed May 28, 2015."},{"key":"5365_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, Pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u2013648.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240\u2013251.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1365-2036.2009.04142.x","volume":"15","author":"R Jones","year":"2009","unstructured":"Jones R, Junghard O, Dent J, et al. Development of the Gerd Q, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;15:1030\u20131038.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/2050640613485238","volume":"1","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. U Eur Gastroenterol J. 2013;1:175\u2013183.","journal-title":"U Eur Gastroenterol J."},{"key":"5365_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888\u2013891.","journal-title":"J Gastroenterol."},{"key":"5365_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2036.2006.02774.x","volume":"23","author":"SJ Veldhuyzen Van Zanten","year":"2006","unstructured":"Veldhuyzen Van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point global overall symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006;23:521\u2013529.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/gut.45.2.172","volume":"45","author":"LR Lundell","year":"1999","unstructured":"Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172\u2013180.","journal-title":"Gut."},{"key":"5365_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1442-2050.2007.00788.x","volume":"21","author":"H Miwa","year":"2008","unstructured":"Miwa H, Yokoyama T, Hori K, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus. 2008;21:355\u2013363.","journal-title":"Dis Esophagus."},{"key":"5365_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1055\/s-0028-1098086","volume":"1","author":"K Kimura","year":"1969","unstructured":"Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87\u201397.","journal-title":"Endoscopy."},{"key":"5365_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u2013730.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1053\/gast.1996.v111.pm8898633","volume":"111","author":"NA Tobey","year":"1996","unstructured":"Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux\u2013damaged human esophageal epithelium. Gastroenterology. 1996;111:1200\u20131205.","journal-title":"Gastroenterology."},{"key":"5365_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.gastro.2004.08.014","volume":"128","author":"WJ Barlow","year":"2005","unstructured":"Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128:771\u2013778.","journal-title":"Gastroenterology."},{"key":"5365_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.gastro.2007.12.010","volume":"134","author":"R Fass","year":"2008","unstructured":"Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology. 2008;134:696\u2013705.","journal-title":"Gastroenterology."},{"key":"5365_CR27","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1053\/j.gastro.2009.07.055","volume":"137","author":"RF Souza","year":"2009","unstructured":"Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776\u20131784.","journal-title":"Gastroenterology."},{"key":"5365_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jgh.12139","volume":"28","author":"J Shan","year":"2013","unstructured":"Shan J, Oshima T, Fukui H, Watari J, Miwa H. Acidic deoxycholic acid and chenodeoxycholic acid induce interleukin-8 production through p38 mitogen-activated protein kinase and protein kinase A in a squamous epithelial model. J Gastroenterol Hepatol. 2013;28:823\u2013828.","journal-title":"J Gastroenterol Hepatol."},{"key":"5365_CR29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","volume":"150","author":"Q Aziz","year":"2016","unstructured":"Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal disorders. Gastroenterology. 2016;150:1368\u20131379.","journal-title":"Gastroenterology."},{"key":"5365_CR30","first-page":"6","volume":"8","author":"MB Fennerty","year":"2006","unstructured":"Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. Med. Gen Med. 2006;8:6.","journal-title":"Med. Gen Med."},{"key":"5365_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13876","volume":"45","author":"H Miwa","year":"2017","unstructured":"Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers\u2014results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45:240\u2013252.","journal-title":"Aliment Pharmacol Ther."},{"key":"5365_CR32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042\u20131051.","journal-title":"Gut."}],"updated-by":[{"DOI":"10.1007\/s10620-019-5464-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000}}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5365-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:14:55Z","timestamp":1573344895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5365-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5365"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5365-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10620-019-5464-6","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,10]]},"assertion":[{"value":"24 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of the article unfortunately contained percentage errors in second and third paragraphs of GerdQ Score section. Below is the corrected version.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}